TARA Protara Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TARA

Price (delayed)

$2.91

Market cap

$59.92M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.74

Enterprise value

$12.91M

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara's portfolio includes its lead program, TARA-002, an investigational cell-based ...

Highlights
The debt has decreased by 15% YoY and by 4.4% from the previous quarter
The EPS has increased by 34% year-on-year but it has declined by 4.8% since the previous quarter
The company's net income rose by 34% YoY but it fell by 5% QoQ
The equity has declined by 38% year-on-year and by 15% since the previous quarter
Protara Therapeutics's quick ratio has decreased by 26% YoY and by 6% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://protaratx.com/
Peers: OMER OMGA

Key stats

What are the main financial stats of TARA
Market
Shares outstanding
20.59M
Market cap
$59.92M
Enterprise value
$12.91M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.57
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$42.47M
EBITDA
-$42.12M
Free cash flow
-$35.09M
Per share
EPS
-$3.74
Free cash flow per share
-$3.07
Book value per share
$5.11
Revenue per share
$0
TBVPS
$5.97
Balance sheet
Total assets
$68.13M
Total liabilities
$9.73M
Debt
$5.23M
Equity
$58.41M
Working capital
$52.41M
Liquidity
Debt to equity
0.09
Current ratio
10.53
Quick ratio
10.04
Net debt/EBITDA
1.12
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-51.4%
Return on equity
-58.8%
Return on invested capital
-99.9%
Return on capital employed
-67.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TARA stock price

How has the Protara Therapeutics stock price performed over time
Intraday
0.69%
1 week
-0.34%
1 month
-29.02%
1 year
-5.83%
YTD
55.19%
QTD
-27.43%

Financial performance

How have Protara Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$45.73M
Net income
-$42.47M
Gross margin
N/A
Net margin
N/A
The company's net income rose by 34% YoY but it fell by 5% QoQ
TARA's operating income is up by 31% year-on-year but it is down by 4.9% since the previous quarter

Growth

What is Protara Therapeutics's growth rate over time

Valuation

What is Protara Therapeutics stock price valuation
P/E
N/A
P/B
0.57
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 34% year-on-year but it has declined by 4.8% since the previous quarter
TARA's P/B is 43% above its last 4 quarters average of 0.4 but 19% below its 5-year quarterly average of 0.7
The equity has declined by 38% year-on-year and by 15% since the previous quarter

Efficiency

How efficient is Protara Therapeutics business performance
TARA's return on invested capital is down by 48% since the previous quarter and by 34% year-on-year
TARA's ROE is down by 18% since the previous quarter and by 10% year-on-year
The ROA has contracted by 17% from the previous quarter and by 4.7% YoY

Dividends

What is TARA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TARA.

Financial health

How did Protara Therapeutics financials performed over time
The total assets has declined by 36% year-on-year and by 14% since the previous quarter
Protara Therapeutics's current ratio has decreased by 29% YoY and by 6% from the previous quarter
The debt is 91% less than the equity
The equity has declined by 38% year-on-year and by 15% since the previous quarter
Protara Therapeutics's debt to equity has increased by 29% YoY and by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.